ReviewNanoscale advances2026
Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.
Review in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aggressive and extremely diverse subtype of breast cancer known as triple-negative breast cancer (TNBC) lacks HER2, progesterone, and oestrogen receptors, which limits treatment options and increases the risk of metastasis and recurrence. Because of TNBC's complex tumour microenvironment (TME), genetic variety, and innate drug resistance, conventional therapies like chemotherapy and radiotherapy frequently cause severe systemic toxicity and have poor efficacy. By improving targeted delivery, reducing off-target effects, and facilitating multimodal therapy options, nanocarrier-based drug delivery devices provide a revolutionary strategy for TNBC. The ability of several nanocarrier platforms, such as liposomes, dendrimers, polymeric nanoparticles (NPs), and quantum dots, to target TNBC's distinct TME
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.